Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

Authors: Fadia J A Gujam, James J Going, Zahra M A Mohammed, Clare Orange, Joanne Edwards, Donald C McMillan

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Lymphovascular invasion (LBVI) including lymphatic (LVI) and blood (BVI) vessel invasion is a critical step in cancer metastasis. In breast cancer, the optimal detection method of LBVI remains unclear. This research aimed to compare the prognostic value of different assessments of the LVI and BVI in patients with early breast cancer.

Methods

The study cohort included 360 patients with a median follow-up of 168 months. LBVI on H&E sections (LBVIH&E) was reviewed centrally and blinded to the pathology report. Immunohistochemical staining for D2-40 and Factor VIII was performed to identify LVID2–40 and BVIFVIII.

Results

LBVIH&E, LVID2–40 and BVIFVIII were present in 102 (28%), 127 (35%) and 59 (16%) patients respectively. In node-negative patients (206), LBVIH&E, LVID2–40 and BVIFVIII were present in 41 (20%), 53 (26%) and 21 (10%) respectively. In triple-negative patients (120), LBVIH&E, LVID2–40 and BVIFVIII were present in 35 (29%), 46 (38%) and 16 (13%) respectively. LBVIH&E was significantly associated with tumour recurrence in the whole cohort (P < 0.001), node-negative patients (P = 0.001) and triple-negative patients (P = 0.004). LVID2–40 and BVIFVIII were significantly associated with tumour recurrence in whole cohort, node-negative (all P < 0.001) and triple-negative patients (P = 0.002). In multivariate survival analysis, only LVID2–40 and BVIFVIII were independent predictors of cancer specific survival in the whole cohort (P = 0.023 and P < 0.001 respectively), node-negative patients (P = 0.004 and P = 0.001 respectively) and triple-negative patients (P = 0.014 and P = 0.001 respectively).

Conclusion

Assessment of LVI and BVI by IHC using D2-40 and Factor VIII improves prediction of outcome in patients with node-negative and triple-negative breast cancer.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Parkin D, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46: 765-781. 10.1016/j.ejca.2009.12.014.CrossRefPubMed
2.
3.
Rosai J, Sobin L: Tumors of the Mammary Gland. 1993, Washington: DC: Armed Forces Institute of Pathology
4.
Gilchrist KW, Gould VE, Hirschl S, Imbriglia JE, Patchefsky AS, Penner DW, Pickren J, Schwartz IS, Wheeler JE, Barnes JM, Mansour EG: Interobserver variation in the identification of breast-carcinoma in intra-mammary lymphatics. Hum Pathol. 1982, 13: 170-172. 10.1016/S0046-8177(82)80121-4.CrossRefPubMed
5.
Teel P: Vascular invasion as a prognostic factor in breast carcinoma. Surg Gynecol Obstetrics. 1964, 118: 1006-1008.
6.
Davis BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russell I, Rudenstam CM: Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985, 16: 1212-1218. 10.1016/S0046-8177(85)80033-2.CrossRefPubMed
7.
Bettelheim R, Mitchell D, Gusterson BA: Immunocytochemistry in the identification of vascular invasion in breast-cancer. J Clin Pathol. 1984, 37: 364-366. 10.1136/jcp.37.4.364.CrossRefPubMedPubMedCentral
8.
Pinder SE, Ellis IO, Galea M, Orourke S, Blamey RW, Elston CW: Pathological prognostic factors in breast-cancer.III. Vascular invasion – relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994, 24: 41-47. 10.1111/j.1365-2559.1994.tb01269.x.CrossRefPubMed
9.
de Mascarel I, Bonichon F, Durand M, Mauriac LH, Macgrogan G, Soubeyran I, Picot V, Avril A, Coindre JM, Trojani M: Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998, 34: 58-65. 10.1016/S0959-8049(97)00344-4.CrossRefPubMed
10.
McCready DR, Chapman JAW, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley LA: Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol. 2000, 7: 416-426. 10.1007/s10434-000-0416-z.CrossRefPubMed
11.
Lee AHS, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, Blamey RW: Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006, 42: 357-362. 10.1016/j.ejca.2005.10.021.CrossRefPubMed
12.
Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M: Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009, 116: 317-328. 10.1007/s10549-008-0206-z.CrossRefPubMed
13.
Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, Mouridsen HT, on behalf of the Danish Breast Cancer Cooperative Group: Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2009, 101: 729-735. 10.1093/jnci/djp090.CrossRefPubMed
14.
Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, de Lara CT, Muriac L, de Mascarel I: Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?. Cancer. 2010, 116: 3093-3101. 10.1002/cncr.25137.CrossRefPubMed
15.
Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M: The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer. 2003, 88: 1900-1908. 10.1038/sj.bjc.6600921.CrossRefPubMedPubMedCentral
16.
Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO: Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007, 31: 1825-1833. 10.1097/PAS.0b013e31806841f6.CrossRefPubMed
17.
Mohammed RA, Martin SG, Mahmmod AM, Green AR, Paish EC, Ellis IO: Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011, 223: 358-365. 10.1002/path.2810.CrossRefPubMed
18.
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SE, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Archives Pathol Lab Med. 2000, 124: 966-978.
19.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann T, Senn HJ: Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2009, 20: 1319-1329. 10.1093/annonc/mdp322.CrossRefPubMedPubMedCentral
20.
Wittekind C, Hutter R, Grenee FL, Klimpfinger M, Sobin LH: TNM Atlas: Illustrated Guideline to the TNM Classification of Malignant Tuomurs. 2005, New York: WileyCrossRef
21.
Saigo PE, Rosen PP: The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer. 1987, 59: 51-54. 10.1002/1097-0142(19870101)59:1<51::AID-CNCR2820590114>3.0.CO;2-5.CrossRefPubMed
22.
Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Dirix L, Vermeulen P, Van Marck E: Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006, 94: 1643-1649.PubMedPubMedCentral
23.
Hoda SA, Hoda RS, Merlin S, Shamonki J, Rivera M: Issues relating to lymphovascular invasion in breast carcinoma. Adv Anat Pathol. 2006, 13: 308-315. 10.1097/01.pap.0000213048.69564.26.CrossRefPubMed
24.
Gujam FJA, Going JJ, Edwards J, Mohammed ZM, McMillan DC: The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Critical Rev Oncol Hematol. 2014, 89: 231-241. 10.1016/j.critrevonc.2013.08.014.CrossRef
25.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.CrossRefPubMedPubMedCentral
26.
Mohammed ZMA, Going JJ, McMillan DC, Mallon E, Doughty JC, Edwards J: Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology. 2012, 61: 675-684.CrossRefPubMed
27.
Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R: Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004, 240: 306-312. 10.1097/01.sla.0000133355.48672.22.CrossRefPubMedPubMedCentral
28.
Yamauchi C, Hasebe T, Iwasaki M, Imoto S, Wada N, Fukayama M, Ochiai A: Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol. 2007, 38: 247-259. 10.1016/j.humpath.2006.07.017.CrossRefPubMed
29.
Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M: Blood vessel invasion as a predictor of long-term survival for Japanese patients with breast cancer. Breast Cancer Res Treat. 2002, 73: 1-12. 10.1023/A:1015224703057.CrossRefPubMed
30.
Kato T, Kimura T, Miyakawa R, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T: Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer. 2000, 82: 404-411. 10.1054/bjoc.1999.0934.CrossRefPubMedPubMedCentral
31.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008, 14: 5158-5165. 10.1158/1078-0432.CCR-07-4756.CrossRefPubMed
32.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10: R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral
33.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van’t Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed
34.
Lauria R, Perrone F, Carlomagno C, Delaurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, Deplacido S: The prognostic value of lymphatic and blood-vessel invasion in operable breast-cancer. Cancer. 1995, 76: 1772-1778. 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O.CrossRefPubMed
35.
Lee AK, Delellis RA, Silverman ML, Heatley GJ, Wolfe HJ: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clinical Oncol Official J Am Soc Clinical Oncol. 1990, 8: 1457-1465.
36.
Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S: Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res. 2001, 21: 2351-2355.PubMed
37.
Kaiserling E: Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology. Pathologe. 2004, 25: 362-373.CrossRefPubMed
38.
Arigami T, Natsugoe S, Uenosono Y, Arima H, Mataki Y, Ehi K, Yanagida S, Ishigami S, Hokita S, Aikou T: Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer. 2005, 93: 688-693. 10.1038/sj.bjc.6602739.CrossRefPubMedPubMedCentral
39.
Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN: Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007, 20: 183-191. 10.1038/modpathol.3800728.CrossRefPubMed
40.
Rabban JT, Chen YY: D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol. 2008, 39: 175-183. 10.1016/j.humpath.2007.06.018.CrossRefPubMed
41.
Martin SA, Perez-Reyes N, Mendelsohn G: Angioinvasion in breast carcinoma. An immunohistochem VIII-Related Antigen Cancer. 1987, 59: 1918-1922.
42.
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet endothelial-cell adhesion molecule antibodies, as indicator of node metastases and survival in breast-cancer. Lancet. 1992, 340: 1120-1124. 10.1016/0140-6736(92)93150-L.CrossRefPubMed
43.
Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL: Tumor angiogenesis in node-negative breast carcinomas - relationship with epidermal growth-factor receptor, estrogen-receptor, and survival. Breast Cancer Res Treat. 1994, 29: 109-116. 10.1007/BF00666186.CrossRefPubMed
44.
Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dallapalma P, Caffo C, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, P53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast-carcinoma. J Clin Oncol. 1994, 12: 454-466.PubMed
Metadata
Title
Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer
Authors
Fadia J A Gujam
James J Going
Zahra M A Mohammed
Clare Orange
Joanne Edwards
Donald C McMillan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-676

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells

Research article

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

Research article

MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2in laryngeal carcinoma

Research article

Tumors induce coordinate growth of artery, vein, and lymphatic vessel triads

Research article

Predicting invasive breast cancer versus DCIS in different age groups

Research article

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits